Search

Your search keyword '"Arnan Sangerman Montserrat"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Arnan Sangerman Montserrat" Remove constraint Author: "Arnan Sangerman Montserrat" Search Limiters Full Text Remove constraint Search Limiters: Full Text
38 results on '"Arnan Sangerman Montserrat"'

Search Results

1. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes

2. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

3. Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

4. Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

5. ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

6. Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

7. Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

8. Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

9. Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1β Inhibitors

10. Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

11. Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

12. Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

13. Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

14. Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

15. Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

16. Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

17. Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

18. Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

19. LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

20. Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

21. Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

23. Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

24. Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

26. Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

27. Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

28. Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

29. Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

30. FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

31. Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with De Novo Mutated NPM1 (NPM1mut) acute Myeloid Leukemia

32. New Score Prognostic System for Patients with MDS and Intermediate IPSS-R: Novel Algorithm to Distinguish Between Low and High Risk in This Subset of Patients. Results from the Spanish Group of MDS (GESMD). Gesmdi Score

33. Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

34. ERCC6L2in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

35. Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

36. Prognostic Impact of the Interaction between DNMT3Amutation and Internal Tandem Duplication of the FLT3Gene (FLT3-ITD)in Patients with De NovoMutated NPM1 (NPM1mut) acute Myeloid Leukemia

37. An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

38. Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis

Catalog

Books, media, physical & digital resources